Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jad Chahoud"'
Autor:
Brian D. Gonzalez, Scott M. Gilbert, Julio M. Pow-Sang, Philippe E. Spiess, Adele Semaan, Laura B. Oswald, Firas Safa, Jad Chahoud, Adi Diab, Houssein Safa, Monica Tamil, Brandon J. Manley
Publikováno v:
J Natl Cancer Inst
Background Patient-reported outcomes (PROs) promote patient centeredness in clinical trials; however, in the field of rapidly emerging and clinically impressive immunotherapy, data on PROs are limited. Methods We systematically identified all immunot
Autor:
Safae Terrisse, E. Karamouza, Bjørn Erikstein, Chris Parker, Sigbjørn Smeland, Laurence Collette, Nicholas D. James, Gwénaël Le Teuff, Karim Fizazi, Sarah Pirrie, Jad Chahoud, Bertrand F. Tombal, A. Oliver Sartor, Jean-Pierre Pignon
Publikováno v:
JAMA Oncology, Vol. 6, no. 2, p. 206-216 (2020)
IMPORTANCE Both α-emitting and β-emitting bone-targeted radioisotopes (RIs) have been developed to treat men with metastatic castration-resistant prostate cancer (CRPC). Only 1 phase 3 randomized clinical trial has demonstrated an overall survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd17d3d7c0c10af995a84e80d7ad4e55
https://hdl.handle.net/2078.1/223808
https://hdl.handle.net/2078.1/223808
Autor:
Karim Fizazi, Laurence Collette, Jean-Pierre Pignon, Chris Parker, Sigbjørn Smeland, Safae Terrisse, Karamouza Eleni, A. Oliver Sartor, Gwénaël Le Teuff, Nicholas D. James, Sarah Pirrie, Bertrand F. Tombal, Jad Chahoud, Bjørn Erisktein
Publikováno v:
Journal of Clinical Oncology. 36:352-352
352 Background: Among bone-targeted radio-isotopes (RI), Radium-223 (an α-emitter) is the only one with clearly demonstrated overall survival (OS) benefit in men with castration-resistant prostate cancer (CRPC). The aim of this meta-analysis is to e